IKAROS family zinc finger 4Genealiases: EOS · ZNFN1A4
Q-omics provides the consensus-scored IKZF4 profile across patient tissues and cancer cell-line models. IKZF4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, IKZF4 is differentially expressed in 12, with the highest sampling consensus in LIHC. Additionally, IKZF4 RNA expression shows 20,350 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, LIHC, and THYM as cancer lineages where IKZF4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IKZF4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IKZF4 survival associations across molecular data types. IKZF4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IKZF4 RNA expression–survival associations across cancer types. High IKZF4 expression shows unfavorable associations in LGG, but favorable associations in LUAD, HNSC, ACC, BRCA and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for IKZF4 RNA expression.
This table summarizes IKZF4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for IKZF4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IKZF4 shows lower tumor expression in UCEC, LUSC, BRCA and LUAD and higher tumor expression in LIHC and CHOL. The LIHC box plot shows higher IKZF4 RNA expression in tumor versus normal tissue (log2 FC = +0.680, t-test p < 0.001).
This table shows molecular features associated with IKZF4 in patient tissues and cancer cell lines. In patient samples, IKZF4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IKZF4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
